Start with a free account for 3 free CME credits. Already a subscriber? Sign in.

Paper Chase 4: Anticoagulant Treatment for Unprovoked Pulmonary Embolism

Andrew Buelt, DO and Joe Weatherly, DO
00:00
05:41
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

Among patients with a first episode of unprovoked pulmonary embolism who received 6 months of anticoagulant treatment, an additional 18 months of treatment with warfarin reduced the composite outcome of recurrent venous thrombosis and major bleeding compared with placebo.

 

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

Robert S., MD -

Maybe the reason that the two groups' rate of PE began to merge after the end of the coumadin was that these patients have a propensity to develop PE's and perhaps this study suggests that coumadin should continue longer (although then you have to balance the benefits of reduced PE's with the risk of coumadin).

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
The Allergy That Isn't and the B-12 That Is Full episode audio for MD edition 183:18 min - 86 MB - M4AHippo Primary Care RAP February 2016 Summary 735 KB - PDF